Cite
Cardio-renal outcomes with long-term agalsidase alfa enzyme replacement therapy: A 10-year Fabry Outcome Survey analysis.
MLA
Ramaswami, Uma, et al. “Cardio-Renal Outcomes with Long-Term Agalsidase Alfa Enzyme Replacement Therapy: A 10-Year Fabry Outcome Survey Analysis.” Molecular Genetics & Metabolism, vol. 117, no. 2, Feb. 2016, p. S98. EBSCOhost, https://doi.org/10.1016/j.ymgme.2015.12.416.
APA
Ramaswami, U., Beck, M., Hughes, D., Kampmann, C., Bizjajeva, S., Pintos-Morell, G., West, M., Niu, D.-M., Nicholls, K., & Giugliani, R. (2016). Cardio-renal outcomes with long-term agalsidase alfa enzyme replacement therapy: A 10-year Fabry Outcome Survey analysis. Molecular Genetics & Metabolism, 117(2), S98. https://doi.org/10.1016/j.ymgme.2015.12.416
Chicago
Ramaswami, Uma, Michael Beck, Derralynn Hughes, Christoph Kampmann, Svetlana Bizjajeva, Guillem Pintos-Morell, Michael West, Dau-Ming Niu, Kathy Nicholls, and Roberto Giugliani. 2016. “Cardio-Renal Outcomes with Long-Term Agalsidase Alfa Enzyme Replacement Therapy: A 10-Year Fabry Outcome Survey Analysis.” Molecular Genetics & Metabolism 117 (2): S98. doi:10.1016/j.ymgme.2015.12.416.